Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting |
[30-September-2024] |
OSLO, Norway, Sept. 30, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira® (APL-1702) for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) has been published by the 27th Chinese Society of Clinical Oncology (CSCO) Annual Meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month pathological regression rate and HPV clearance rate. This Phase III clinical trial is a prospective, randomized, double blind, placebo controlled, multi-center clinical study, which has reached its primary efficacy endpoint and exhibited good safety. Furthermore, the study results included the pathological regression rate (defined as the proportion of subjects with a pathological regression to CIN1 or normal tissue) at the 6th month across different age subgroups. Both the "≥20 and <30 years" subgroup and the "≥30 and <40 years" subgroup showed an increase of 15% to 20% in the pathological regression rate in the APL-1702 group compared to the placebo control group. No cervical cancer events were reported, suggesting a significant therapeutic potential of APL-1702 in the HSIL population aged 20 to 40 years. Regarding HPV clearance rate, in the "≥20 and <30 years" age group, the APL-1702 group showed enhancements in the overall HPV clearance rate, HPV16-positive clearance rate, and HPV16/18-positive clearance rate compared to the placebo control group. The patients' number in the "<20 years" and "≥40 years" age groups were limited, thus the results in these age groups require a validation study with a larger sample size. Overall, APL-1702 not only facilitates the regression from HSIL to LSIL but also demonstrates the ability to induce clearance of high-risk HPV infections. Read Asieris' full media release here: https://asieris.com/asieris-unveils-results-for-the-first-time-at-2024-csco-conference-the-subgroup-analysis-of-pathological-regression-rate-and-hpv-clearance-rate-at-6-months-in-different-age-groups-of-the-non-surgical/ Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. About Cevira® About Photocure ASA About Asieris For further information, please contact: Dan Schneider Erik Dahl David Moskowitz Media and IR enquiries: Geir Bjørlo
This information was brought to you by Cision http://news.cision.com The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age-groups-at-the-2024-csco-annual-meeting-302262259.html SOURCE Photocure | ||
Company Codes: Bloomberg:PHO@NO, ISIN:NO0010000045, Oslo:PHO, RICS:PHO.OL |